Quality Culture and Knowledge Management in the Japanese Pharmaceutical Industry—A Cross-Sectional Study and Case Report

References

1. 1.↵
   Chemo-Sero-Therapeutic Research Institute (Kaketsuken). Investigation Report. November 25, 2015. https://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000106165.pdf (accessed May 8, 2023).
2. 2.↵
   Director of Evaluation and Licensing Division, PSEB, MHLW. Notification 0119 No. 1. Regarding the Implementation of Inspections Related to the Consistency between Manufacturing and Marketing Approval for Pharmaceutical Products and the Actual Manufacturing Conditions. January 19, 2016. https://www.mhlw.go.jp/web/t_doc?dataId=00tc1544&dataType=1&pageNo=1 (accessed Aug 5, 2023).
3. 3.↵
   Ministry of Health, Labour and Welfare. Results of a Broad Inspection of the Manufacturing and Marketing Approval for Pharmaceutical Products and Actual Manufacturing Conditions. June 1, 2016. https://www.mhlw.go.jp/stf/houdou/0000126263.html (accessed May 8, 2023).
4. 4.↵
   Japan BCG Laboratory. Regarding Administrative Disposition Related to Violations of the Pharmaceuticals and Medical Devices Act. April 26, 2016. https://www.bcg.gr.jp/news/news_160426.pdf (accessed May 8, 2023).
5. 5.↵
   Matsuura Yakugyo Co., Ltd. Apology and Notice Regarding Administrative Disposition on Our Company. August 8, 2019. https://www.matsuura-gp.co.jp/etc/doc/2016032921413222_32.pdf (accessed May 8, 2023).
6. 6.↵
   Kyowa Kirin Co., Ltd. Regarding Administrative Disposition on Kyowa Hakko Bio Co., Ltd. December 2019. https://www.kyowakirin.co.jp/information/2019/pdf/20191224_01.pdf (accessed May 8, 2023).
7. 7.↵
   Ministry of Health, Labour and Welfare of Japan. Regarding Administrative Disposition Related to Violations of the Pharmaceuticals and Medical Devices Act April 28, 2021. https://www.mhlw.go.jp/stf/newpage_18351.html (accessed Aug 5, 2023).
8. 8.↵
   Nichi-Iko Pharmaceutical Co., Ltd. Regarding Administrative Disposition on Our Company. March 3, 2021. https://www.nichiiko.co.jp/company/press/detail/5087/1301/4541_20210303_01.pdf (accessed May 8, 2023).
9. 9.↵
   Choseido Pharmaceutical Co., Ltd. Regarding Administrative Disposition Based on the Pharmaceuticals and Medical Devices Act. October 11, 2021. https://www.choseido.com/news/pdf/211011.pdf (accessed May 8, 2023).
10. 10.↵
    Ministry of Health, Labour and Welfare of Japan. Ordinance No. 90. Ministerial Ordinance to Partially Revise the Ministerial Ordinances on Standards of Manufacturing and Quality Controls of Pharmaceutical and Quasi-Pharmaceutical Products. Released on April 28, 2021; Implemented on August 1, 2021. https://elaws.e-gov.go.jp/document?lawid=416M60000100179_20210801_503M60000100090 (accessed Aug 5, 2023).
11. 11.↵
    Ministry of Health, Labour and Welfare of Japan. Regarding the case of Kobayashi Kako Co., Ltd.'s Itraconazole containing hypnotic. March 12, 2021. https://www.mhlw.go.jp/content/11120000/000751984.pdf (accessed Aug 5, 2023).
12. 12.↵
    Special Investigation Committee. Investigation Report (Summary Version). April 16, 2021. https://ajhc.or.jp/siryo/f20210416-3.pdf (accessed Aug 5, 2023).
13. 13.↵
    Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S). PIC/S Guidance, Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments. PI 041-1. PIC/S: Geneva, 2021.
14. 14.↵
    Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S). Guide to Good Manufacturing Practice for Medicinal Products Part 1. Feb 1, 2022. https://picscheme.org/docview/4588 (accessed Aug 5, 2023).
15. 15.↵
    International Conference for Harmonisation. ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. ICH: Geneva, 2008. https://www.pmda.go.jp/files/000156592.pdf (accessed May 8, 2023).
16. 16.↵
    Pharmaceutical and Food Safety Bureau Compliance and Narcotics Division. Regarding Guidelines for Pharmaceutical Quality Systems. PFSB/ELD Notification No. 0219-1. February 19, 2010. https://www.pmda.go.jp/files/000156141.pdf (accessed May 8, 2023).
17. 17.↵
    Ministry of Health, Labour and Welfare. Director-General of Pharmaceutical Safety and Environmental Bureau. PSEB Notification No. 1204-1. Regarding the Release of Act to Revise a Part of Act regarding Ensuring Quality, Effectiveness, and Safety of Pharmaceutical Products and Medical Devices. December 4, 2019. https://www.mhlw.go.jp/web/t_doc?dataId=00tc4641&dataType=1&pageNo=1 (accessed May 8, 2023).
18. 18.↵
    Federation of Pharmaceutical Manufacturers' Associations of Japan. Notification No: 704. Regarding Questionnaire on the Status of Efforts for Knowledge Management and Fostering of Quality Culture (Cooperation Request). September 13, 2021.
19. 19.↵
    Ministry of Health, Labour and Welfare Grants System. Research on International Harmonization of Guidelines of GMP, QMS and GCTP. 2020. https://mhlw-grants.niph.go.jp/project/149575 (accessed May 8, 2023).
20. 20.↵
    Federation of Pharmaceutical Manufacturers' Associations of Japan. February 2022. http://www.fpmaj.gr.jp/ (accessed May 8, 2023).
21. 21.↵
    Japan Bulk Pharmaceutical Manufacturers Association. February 2022. https://jbpma.gr.jp/ (accessed May 8, 2023).
22. 22.↵
    PRAISE-NET. February 2022. https://www.praise-net.jp/ (accessed May 8, 2023).
23. 23.↵
    Ministry of Health, Labour and Welfare. Act Regarding Ensuring Quality, Effectiveness, and Safety of Pharmaceutical Products and Medical Devices (1952 Judiciary No. 145). Implemented on August 1, 2021 (Amendment by 2019 Act No. 63). Article 14. https://elaws.e-gov.go.jp/document?lawid=335AC0000000145 (accessed May 8, 2023).
24. 24.↵
    Pharmaceuticals and Medical Devices Agency. Regarding Guidelines for the Items to be Stated in the Application for the Manufacturing and Marketing Approval of Pharmaceutical Products Based on PMDA and the Revised Pharmaceutical Affairs Act. PFSB/ELD Notification No. 0210001. February 10, 2005. https://www.pmda.go.jp/files/000160084.pdf (accessed May 8, 2023).
25. 25.↵
    1952 Ministry of Health and Welfare. Ordinance No. 1. Enforcement Regulations of Act regarding Ensuring Quality, Effectiveness, and Safety of Pharmaceutical Products and Medical Devices. Article 47. Implemented on December 14, 2019. https://elaws.e-gov.go.jp/document?lawid=336M50000100001_20191214_501M60000100070 (accessed May 8, 2023).
26. 26.↵
    International Conference for Harmonisation. Harmonised Tripartite Guideline Q8: Pharmaceutical Development. ICH: Geneva, 2009. https://www.pmda.go.jp/files/000156835.pdf (accessed May 8, 2023).
27. 27.↵
    1. Nonaka I.

    A Dynamic Theory of Organizational Knowledge Creation. Organ. Sci. 1994, 5 (1), 14–37.

    OpenUrlCrossRefWeb of Science
28. 28.↵
    U.S. Food and Drug Administration. Pharmaceutical CGMPs for the 21st Century – A Risk-Based Approach. U.S. Department of Health and Human Services: Rockville, MD, 2004. https://www.fda.gov/media/77391/download (accessed Aug 5, 2023)
29. 29.↵
    Japan Generic Medicines Association. Regarding the initiatives for trust recovery in generic medicines. March 26, 2021. https://www.jga.gr.jp/news/210326_004466.html (accessed May 8, 2023)
30. 30.↵
    Ministry of Health, Labour and Welfare, Director-General of Pharmaceutical Safety and Environmental Bureau. PSEB Notification No. 0129-5. Regarding Guideline of Law Compliance for Marketing Authorization Holder and Manufacturer. January 29, 2021.